You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Factor VIII

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Severe Hemophilia A Without Inhibitor, Joint Bleed Trial in Bangkok ("Emicizumab", "HEMLIBRA®")

Recruiting
  • Severe Hemophilia A Without Inhibitor
  • Joint Bleed
  • "Emicizumab", "HEMLIBRA®"
  • Bangkok, Thailand
    King Chulalongkorn Memorial hospital
Nov 25, 2023

Dynamics of Anti-factor VIII Antibody Signature During Treatment

Not yet recruiting
  • Severe Hemophilia A
  • +2 more
  • no interventions
  • (no location specified)
Apr 4, 2023

Hemophilia A Trial in Milwaukee (Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human

Recruiting
  • Hemophilia A
  • Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII
  • Milwaukee, Wisconsin
    Froedtert Hospital and the Medical College of Wisconsin
Dec 21, 2022

Elevated Factor VIII Related Labs asBiomarker for Incomplete

Not yet recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • blood tests drawn days 1, 8, 22 and 90 of the study
  • (no location specified)
Jun 22, 2023

A Prospective and Retrospective Interventional Study on

Recruiting
  • Severe Hemophilia A Without Inhibitor
  • serum biomarker.
  • Taipei, Neihu Dist., Taiwan
    Tri-Service General Hospital Hemophilia Care Center
Aug 10, 2023

Genetic Factors Influencing Desmopressin's Efficacy in

Recruiting
  • Hemophilia A, Mild
  • +2 more
  • Rennes, Bretagne, France
    University hospital of Rennes
Nov 24, 2022

Hemophilia Trial (Coagulation Factor VIIa (Recombinant))

Not yet recruiting
  • Hemophilia
  • Coagulation Factor VIIa (Recombinant)
  • (no location specified)
Jan 12, 2023

Severe Hemophilia A Trial in China (ADVATE, FRSW117)

Completed
  • Severe Hemophilia A
  • Guangzhou, Guangzhou, China
  • +3 more
Jun 27, 2022

Hemophilia A Trial in China (ADVATE, FRSW107)

Recruiting
  • Hemophilia A
  • Beijing, Beijing, China
  • +5 more
Jun 27, 2022

TAK-660 in Surgical Procedures for People With Hemophilia A.

Active, not recruiting
  • Hemophilia A
  • PEGylated Recombinant Factor VIII
  • Tokyo, Japan
    Takeda Selected Site
Dec 13, 2022

Genetic Factors of Desmopressin Response in Carriers of

Completed
  • Carrier of Hemophilia A
  • +2 more
  • Bordeaux, France
  • +11 more
Aug 28, 2023

Bleeding in Moderate and Severe Hemophilia A Playing Sports: A

Not yet recruiting
  • Hemophilia A
  • (no location specified)
Mar 4, 2022

Hemophilia A Trial in France (Virtual-reality (VR) Based Solution)

Not yet recruiting
  • Hemophilia A
  • Virtual-reality (VR) Based Solution
  • Bron, Auvergne-Rhône-Alpes, France
  • +4 more
Jun 24, 2022

Hemophilia A Trial in Tianjin (Single dose intravenous injection of BBM-H803)

Recruiting
  • Hemophilia A
  • Single dose intravenous injection of BBM-H803
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital Chinese Academ
Oct 31, 2023

Children, Teenagers and Severe Hemophilia A Who Switched From

Active, not recruiting
  • Hemophilia A
  • Non-Interventional
  • Hamilton, Ontario, Canada
    Hamilton-Niagara Regional Hemophilia Treatment Centre
Jan 16, 2023

Von Willebrand Disease (VWD) Trial (Recombinant von Willebrand Factor (rVWF), ADVATE)

Not yet recruiting
  • Von Willebrand Disease (VWD)
  • Recombinant von Willebrand Factor (rVWF)
  • ADVATE
  • (no location specified)
Oct 14, 2022

Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII Trial in United Kingdom, United States (Valoctocogene

Recruiting
  • Hemophilia A With Inhibitor
  • Hemophilia A With Anti Factor VIII
  • Valoctocogene roxaparvovec
  • Los Angeles, California
  • +4 more
Aug 2, 2022

Clotting Factor VIII and Bleeding Adverse Reactions in Patients

Withdrawn
  • Bleeding
  • Ischemic Stroke
    • Guangzhou, Guangdong, China
      Zhujiang Hospital of Southern Medical University
    Mar 22, 2022

    Hemophilia A Trial in Worldwide (BAY2599023 (DTX201))

    Active, not recruiting
    • Hemophilia A
    • BAY2599023 (DTX201)
    • Little Rock, Arkansas
    • +12 more
    Jan 5, 2023

    Severe Hemophilia A Trial in Poznan, Krakow (Alphanate SD/HT)

    Completed
    Has Results
    • Severe Hemophilia A
    • Alphanate SD/HT
    • Poznan, Szkolna, Poland
    • +1 more
    May 16, 2022

    Hemophilia Trial in Orange (Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate

    Recruiting
    • Hemophilia
    • Orange, California
      Center for Inherited Blood Disorders (CIBD)-Site Number:8400012
    Feb 2, 2023

    VALIDATE: Factor VIII Trending for MS Relapse

    Withdrawn
    • Multiple Sclerosis
    • Blood sample collection for coagulation profile
    • Phoenix, Arizona
      Barrow Neurological Institute
    Sep 20, 2021

    Severe Hemophilia A Subjects Who Received BMN 270 inPrior

    Enrolling by invitation
    • Hemophilia A
      • London, United Kingdom
        Royal London Hospital, Barts and the London Hemophilia Center
      Mar 13, 2023

      Severe Hemophilia A Trial in Iran, Islamic Republic of (Factor VIII, recombinant human with Fc fusion (rFVIII-Fc))

      Completed
      • Severe Hemophilia A
      • Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)
      • Isfahan, Iran, Islamic Republic of
      • +4 more
      Nov 13, 2023

      Acquired Hemophilia A Trial in United States (OBI-1)

      No longer available
      • Acquired Hemophilia A
      • OBI-1
      • Bethesda, Maryland
      • +3 more
      May 3, 2021